The cost of Gemtesa 75 mg can vary, with common prices ranging from $400 to $500 for a 30-day supply. Prescription assistance programs may be available to help reduce out-of-pocket expenses [1].
What is Gemtesa used for?
Gemtesa (vibegron) is a medication prescribed to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urinary urgency, and urinary frequency in adults [2].
How does Gemtesa work?
Gemtesa is a beta-3 adrenergic agonist. It works by relaxing the detrusor muscle in the bladder, which increases bladder capacity and reduces the involuntary contractions that cause urgency and incontinence [2].
How long does it take for Gemtesa to work?
Many patients experience improvements in OAB symptoms within a few weeks of starting Gemtesa, with continued benefits observed over longer periods of use [2].
What is the difference between Gemtesa and other OAB medications?
Gemtesa offers a different mechanism of action compared to some other OAB treatments, such as anticholinergics. It targets the beta-3 receptors in the bladder muscle, which may lead to fewer side effects for some individuals, like dry mouth, constipation, or cognitive issues [2]. Other OAB medications include drugs like oxybutynin, tolterodine, and mirabegron [3].
Can Gemtesa be taken with other medications?
Gemtesa has a low potential for drug interactions and does not carry a boxed warning for drug interactions. However, it is always advisable to discuss all medications, including over-the-counter drugs and supplements, with a healthcare provider before starting Gemtesa [2].
What are the potential side effects of Gemtesa?
Common side effects of Gemtesa include headache, nasopharyngitis (common cold symptoms), diarrhea, nausea, and upper respiratory tract infection. Serious side effects are rare but can include urinary tract infections and incomplete bladder emptying [2].
When does Gemtesa's patent expire?
Information regarding the specific patent expiry dates for Gemtesa is available through specialized patent tracking resources. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can help determine when exclusivity periods end and potential generic competition might emerge [1].